$ANAC News

Last published 3y ago

3y agoANACArctos NorthStar Acquisition Corp. Announces Redemption of Class A Ordinary SharesBusiness WireArctos NorthStar Acquisition Corp. (NYSE:ANAC) (the "Company") today announced that its board of directors (the "Board") has determined to redeem all of its outstanding Class A ordinary shares (the "Class A Shares"),
5y agoANACStemming from SEC Guidance Concerning Balance Sheet Treatment of Warrants, Arctos NorthStar Acquisition Corp. Announces Receipt of NYSE Continued Listing Standard NoticeBusiness WireArctos NorthStar Acquisition Corp. (NYSE:ANAC) (the "Company") today announced that it received a formal notice of non-compliance from the New York Stock Exchange (the "NYSE") relating to the Company's failure to timely file its Quarterly Report on Form
5y agoANACArctos NorthStar Acquisition Corporation Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing April 15, 2021Business WireDALLAS & NEW YORK--(BUSINESS WIRE)--Arctos NorthStar Acquisition Corporation (NYSE: ANAC.U) (the “Company”) announced that, commencing April 15, 2021, holders of the units sold in the Company’s initial public offering of 31,625,000 units, completed on February 25, 2021, may elect to separately trade the Class A ordinary shares and warrants included in the units. Those units not separated will cont ...
10y agoHTGC WFC TPIC JAZZ+12Hercules Announces Strong Second Quarter Financial Results with $0.32 NII per Share and a $0.31 Quarterly DividendBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, today announced its financial results for the second quarter ended June 30, 2016.
10y agoHTGC JAZZ CPXX PFE+5Hercules Provides Portfolio Update for Q2 2016 and Highlights Continued Execution of Its Portfolio and Earnings Growth StrategyBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth, pre-IPO and M&A stage companies backed by leading venture capital firms, today provided its portfolio update for Q2 2016.
10y agoANACANACOR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Anacor Pharmaceuticals, Inc. (ANAC) Over the Proposed Sale of the Company to Pfizer Inc.Business WireNEW YORK--(BUSINESS WIRE)--Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Anacor Pharmaceuticals, Inc. (“Anacor” or the “Company”) (Nasdaq:ANAC) for potential breaches of fiduciary duties in connection with the sale of the Company to Pfizer Inc. for approximately $5.2 billion.
10y agoPFE ANACPfizer to Acquire AnacorBusiness WireNEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately $5.2 billion, which assumes the conversion of Anacor’s outstanding conv ...
10y agoANACAnacor Pharmaceuticals' (ANAC) CEO Paul Bernson on Q1 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
10y agoANACAnacor Pharmaceuticals Reports First Quarter 2016 Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended March 31, 2016.
10y agoANACAnacor Pharmaceuticals to Report First Quarter 2016 Financial Results on May 10, 2016Business WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will release its financial results for the quarter ended March 31, 2016, before the market opens on Tuesday, May 10, 2016. The announcement will be followed by a conference call at 8:00 a.m. ET / 5:00 a.m. PT during which management will discuss Anacor’s financial results and recent developments. The call may be accesse ...
10y agoANACAnacor Pharmaceuticals to Present at the Deutsche Bank 41st Annual Healthcare ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that the company’s management team will provide a company overview at the Deutsche Bank 41st Annual Healthcare Conference on Thursday, May 5, 2016 at 2:10 p.m. ET / 11:10 a.m. PT in Boston, Massachusetts. The event will be webcast live and may be accessed under “Events and Presentations” on the Investors ...
10y agoANACAnacor Pharmaceuticals, Inc. Announces Pricing of Offering of $250 Million of 2.00% Convertible Senior Notes Due 2023Business WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 2.00% Convertible Senior Notes due 2023 (the “Convertible Notes”) in a private placement under the Securities Act of 1933, as amended (the “Securities Act”). Anacor also granted to the initial purchasers of the Convertible Notes a ...
10y agoANACAnacor Pharmaceuticals, Inc. Announces Proposed Offering of $250 Million of Convertible Senior Notes Due 2023Business WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) announced today that it intends to offer, subject to market and other considerations, $250,000,000 aggregate principal amount of Convertible Senior Notes due 2023 (the “Convertible Notes”) in a private placement under the Securities Act of 1933, as amended (the “Securities Act”). Anacor also intends to grant to the ini ...
10y agoANACAnacor Pharmaceuticals Announces FDA Acceptance of NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic DermatitisBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Anacor’s New Drug Application (NDA) seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-mo ...
10y agoANACAnacor Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that the company’s management team will present at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016 at 9:20 a.m. ET in Boston, Massachusetts. The event will be webcast live and may be accessed under “Events and Presentations” on the Investors page of Anacor’s website a ...
10y agoANACAnacor Pharmaceuticals' (ANAC) CEO Paul Bernson Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts
10y agoANACAnacor Pharmaceuticals (ANAC) Q4 2015 Results - Earnings Call WebcastEarnings Call Transcripts
10y agoANACAnacor Pharmaceuticals Reports 2015 Fourth Quarter and Year-End Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the fourth quarter and year ended December 31, 2015.
10y agoANACAnacor Pharmaceuticals Announces Late-Breaking Oral Presentation of Crisaborole Topical Ointment, 2% Phase 3 Pivotal Data at the 74th Annual Meeting of the American Academy of DermatologyBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that data from its Phase 3 pivotal studies of investigational drug crisaborole topical ointment, 2% will be presented at the 74th Annual Meeting of the American Academy of Dermatology in Washington, D.C. “Crisaborole Topical Ointment, 2%: a Novel, Nonsteroidal, Topical Anti-Inflammatory, Phosphodiesteras ...
10y agoANACAnacor Pharmaceuticals Announces 2015 Fourth Quarter and Year-End Financial Results Conference Call and WebcastBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will release its financial results for the fourth quarter and year ended December 31, 2015, after the market closes on Monday, February 29, 2016. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss Anacor’s financial results and recent developments. ...
10y agoANACAnacor Pharmaceuticals to Present Data From Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis at Upcoming Medical ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that it will present data from the long-term safety study of crisaborole topical ointment, 2% in children and adults with mild-to-moderate atopic dermatitis at the Winter Clinical Dermatology Conference, being held in Koloa, Hawaii from January 15-20, 2016.
10y agoANACAnacor Pharmaceuticals Submits New Drug Application to the FDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic DermatitisBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atop ...
11y agoANACAnacor Pharmaceuticals to Present at the Jefferies Autumn 2015 Global Healthcare ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that the company’s management team will present at the Jefferies Autumn 2015 Global Healthcare Conference on Wednesday, November 18, 2015 at 8:40 a.m. GMT in London, England. The event will be webcast live and may be accessed under “Events and Presentations” on the Investors page of Anacor’s website at w ...
11y agoANACAnacor Pharmaceuticals Reports Third Quarter 2015 Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended September 30, 2015.
11y agoANACAnacor Pharmaceuticals Announces Top-Line Results From Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic DermatitisBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced top-line results from the long-term safety study of Crisaborole Topical Ointment, 2% (formerly AN2728), a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults.
11y agoANACAnacor Pharmaceuticals to Report Third Quarter 2015 Financial Results on November 3, 2015Business WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will release its financial results for the quarter ended September 30, 2015, before the market opens on Tuesday, November 3, 2015. The announcement will be followed by a conference call at 8:00 a.m. ET / 5:00 a.m. PT during which management will discuss Anacor’s financial results and recent developments. The call may be ...
11y agoANACAnacor Pharmaceuticals Announces Presentations of Crisaborole Topical Ointment, 2% Phase 3 Pivotal Data at Two Upcoming Medical ConferencesBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that data from the Phase 3 pivotal studies of investigational drug Crisaborole Topical Ointment, 2% will be presented at two upcoming medical meetings.
11y agoANACAnacor Pharmaceuticals to Present at the Morgan Stanley Global Healthcare ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that the company’s management team will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2015 at 4:15 p.m. ET in New York, New York. The event will be webcast live and may be accessed under “Events and Presentations” on the Investors page of Anacor’s website at www.a ...
11y agoANACAnacor Pharmaceuticals to Present at the 2015 Wedbush PacGrow Healthcare ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company’s Chairman, President and Chief Executive Officer, will provide a company overview at the Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at 12:45 p.m. ET in New York, New York. The event will be webcast live and may be accessed under “Events and Presentatio ...
11y agoANACAnacor Pharmaceuticals Reports Second Quarter 2015 Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended June 30, 2015.
11y agoANACAnacor Pharmaceuticals to Report Second Quarter 2015 Financial Results on August 6, 2015Business WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will release its financial results for the quarter ended June 30, 2015, after the close of market on Thursday, August 6, 2015. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss Anacor’s financial results and recent developments. The call may be acc ...
11y agoANACAnacor Pharmaceuticals Announces Positive Top-Line Results From Two Phase 3 Pivotal Studies of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic DermatitisBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced preliminary top-line results from its two Phase 3 pivotal studies of Crisaborole Topical Ointment, 2% (formerly AN2728), a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and a ...
11y agoANACAnacor Pharmaceuticals to Host Conference Call Tomorrow, July 13, 2015 at 7:30 A.M. ET to Discuss Top-Line Results From Crisaborole Phase 3 Pivotal Studies in Patients With Mild-to-Moderate Atopic DermatitisBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will host a conference call at 7:30 a.m. ET tomorrow, Monday, July 13, 2015 to discuss the top-line results from its Phase 3 pivotal studies of Crisaborole Topical Ointment, 2% (formerly AN2728) for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. A press release announcing the top-l ...
11y agoANACAnacor Pharmaceuticals Announces Amendment to KERYDIN Commercialization AgreementBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced an amendment to its distribution and commercialization agreement with Sandoz Inc., a Novartis company, pursuant to which PharmaDerm, the branded dermatology division of Sandoz, distributes and commercializes KERYDIN® (tavaborole) topical solution, 5%, in the United States. Pursuant to the amendment, Sand ...
11y agoANACAnacor Pharmaceuticals Names Graeme Bell as New Executive Vice President and Chief Financial OfficerBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that Graeme Bell will join Anacor as its new Executive Vice President and Chief Financial Officer. Mr. Bell has more than 20 years of global financial experience in the pharmaceutical industry, and will succeed Geoffrey M. Parker effective as of June 1, 2015. Mr. Parker will remain with Anacor as a consu ...
11y agoANACAnacor Pharmaceuticals to Present at Upcoming Investor ConferencesBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company’s Chairman, President and Chief Executive Officer, will provide a company overview at the following upcoming investor conferences:
11y agoANACAnacor Pharmaceuticals Reports First Quarter 2015 Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended March 31, 2015.
11y agoANACAnacor Pharmaceuticals to Present at Upcoming Investor ConferencesBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company’s Chairman, President and Chief Executive Officer, will provide a company overview at the following upcoming investor conferences:
11y agoANACAnacor Pharmaceuticals Announces First Quarter 2015 Financial Results Conference Call and WebcastBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will release its financial results for the quarter ended March 31, 2015, after the close of market on Wednesday, May 6, 2015. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss Anacor’s financial results and recent developments. The call may be acce ...
11y agoANACAnacor Pharmaceuticals Announces Presentations at the American Academy of Dermatology Annual MeetingBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that the following abstracts have been accepted for presentation at the upcoming 73rd Annual Meeting of the American Academy of Dermatology to be held in San Francisco, California March 20 to 24, 2015:
11y agoANACAnacor Pharmaceuticals Reports 2014 Fourth Quarter and Year-End Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the fourth quarter and year ended December 31, 2014.
11y agoANACAnacor Pharmaceuticals Announces 2014 Fourth Quarter and Year-End Financial Results Conference Call and WebcastBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will release its financial results for the fourth quarter and year ended December 31, 2014, on Thursday, March 12, 2015 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss the company’s financial results ...
11y agoANACAnacor Pharmaceuticals to Present at the 35th Annual Cowen Health Care ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company’s Chairman, President and Chief Executive Officer, will provide a company overview at the 35th Annual Cowen Health Care Conference on Tuesday, March 3, 2015 at 8:00 a.m. ET in Boston, Massachusetts. The event will be webcast live and may be accessed under “Events and Presenta ...
12y agoANACAnacor Pharmaceuticals to Present at the 2014 Credit Suisse Healthcare ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company’s President and Chief Executive Officer, will provide a company overview at the 2014 Credit Suisse Healthcare Conference on Thursday, November 13, 2014 at 9:00 a.m. MT in Phoenix, Arizona. The event will be webcast live and may be accessed under “Events and Presentations” on ...
12y agoANACAnacor Pharmaceuticals Reports Third Quarter 2014 Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended September 30, 2014.
12y agoANACAnacor Pharmaceuticals Announces Third Quarter 2014 Financial Results Conference Call and WebcastBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will release its financial results for the third quarter ended September 30, 2014, on Thursday, November 6, 2014 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss the company’s financial results and rec ...
12y agoANACAnacor Pharmaceuticals, Inc. Announces Pricing of Offering of $75 Million of 2.00% Convertible Senior Notes Due 2021Business WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today the pricing of its offering of $75,000,000 aggregate principal amount of 2.00% Convertible Senior Notes due 2021 (the “Convertible Notes”) in a private placement under the Securities Act of 1933, as amended (the “Securities Act”). Anacor also granted the initial purchasers of the Convertible Notes a 30-d ...
12y agoANACAnacor Pharmaceuticals, Inc. Announces Proposed Offering of $70 Million of Convertible Senior Notes Due 2021Business WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that it intends to offer, subject to market and other considerations, $70,000,000 aggregate principal amount of Convertible Senior Notes due 2021 (the “Convertible Notes”) in a private placement under the Securities Act of 1933, as amended (the “Securities Act”). Anacor also intends to grant to the initi ...
12y agoANACAnacor Pharmaceuticals Announces Commercial Launch of KERYDIN (tavaborole) Topical Solution, 5% in the United StatesBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced the U.S. launch of Anacor’s FDA-approved drug KERYDINTM (tavaborole) topical solution, 5% by Sandoz Inc., a Novartis company. KERYDIN is the first oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed that affects approxima ...
12y agoANACAnacor Pharmaceuticals Appoints Wendell Wierenga to Its Board of DirectorsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that its Board of Directors has appointed Wendell Wierenga, Ph.D. to serve as a Class III director until the Company’s 2016 annual meeting of shareholders. Anacor also announced that Paul Klingenstein has resigned from the Board.